- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Zevra Therapeutics Inc (ZVRA)
Zevra Therapeutics Inc stock price live, this page displays NASDAQ ZVRA stock exchange data. View the ZVRA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Zevra Therapeutics Inc real time stock price chart below.
What Is the Zevra Therapeutics Inc Stock Price Today?
The Zevra Therapeutics Inc stock price today is 8.650.
What Is the Stock Symbol for Zevra Therapeutics Inc?
The stock symbol for Zevra Therapeutics Inc is "ZVRA."
What Stock Exchange Does Zevra Therapeutics Inc Trade On?
Zevra Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Zevra Therapeutics Inc a Good Stock to Buy?
Determining whether Zevra Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ZVRA quote. (ISIN: US4884452065)
What Is the Zevra Therapeutics Inc Stock Price Today?
The Zevra Therapeutics Inc stock price today is 8.650.
What Is the Stock Symbol for Zevra Therapeutics Inc?
The stock symbol for Zevra Therapeutics Inc is "ZVRA."
What Stock Exchange Does Zevra Therapeutics Inc Trade On?
Zevra Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Zevra Therapeutics Inc a Good Stock to Buy?
Determining whether Zevra Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ZVRA quote. (ISIN: US4884452065)
8.650
+0.080(+0.93%)
Closed·
After Hours
8.950+0.310(+3.588%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.425
8.680
52 wk Range
4.200
9.760
ZVRA Scorecard
Full Analysis
Net income is expected to grow this year
ZVRA is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.4258.680
52 wk Range
4.2009.760
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ZVRA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
21.714
Upside
+151.03%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- KemPharm Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- KemPharm Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Zevra Therapeutics Inc Company Profile
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Zevra Therapeutics Inc SWOT Analysis
MIPLYFFA's Triumph | Explore MIPLYFFA's successful launch for Niemann-Pick Disease Type C, with 90 prescriptions written and 30% approved for reimbursement, projecting peak U.S. sales of $230 million by 2028 |
Pipeline Potential | Delve into Zevra's promising pipeline, including KP-1077 for idiopathic hypersomnia and Celiprolol for vascular Ehlers-Danlos syndrome, with clear regulatory pathways ahead |
Financial Outlook | Analysts set a $17 price target, reflecting confidence in Zevra's strong market performance, with a 77.96% stock return over the past year and 47.85% year-over-year revenue growth |
Strategic Assets | Uncover the value of Zevra's Priority Review Voucher, conservatively estimated at $110 million but potentially worth up to $150 million, offering significant financial flexibility |
Zevra Therapeutics Inc Earnings Call Summary for Q1/2025
- Q1 2025: $20.4M revenue, $3.1M net loss (-$0.06/share). Stock up 3.79% after hours to $8.168
- MyPlifa drives revenue; enrolled ~1/3 of NPC patients. Operating expenses down $600K year-over-year
- Cash position $68.7M, boosted by $148.3M PRV sale. Earnings beat forecast despite net loss
- Advancing European regulatory submissions for MyPlifa, expanding global market presence
- CEO optimistic for 2025: continuing MyPlifa/Olpruva launches, progressing Phase III DISCOVER trial
Last Updated: 14/05/2025, 07:24 am
Read Full TranscriptCompare ZVRA to Peers and Sector
Metrics to compare | ZVRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZVRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.1x | −0.1x | −0.4x | |
PEG Ratio | 0.13 | −0.01 | 0.00 | |
Price/Book | 11.5x | 1.5x | 2.6x | |
Price / LTM Sales | 11.7x | 2.5x | 2.9x | |
Upside (Analyst Target) | 154.6% | 308.2% | 51.7% | |
Fair Value Upside | Unlock | 25.8% | 9.5% | Unlock |
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 21.714
(+151.03% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.06 / -0.24
Revenue / Forecast
20.40M / 16.02M
People Also Watch
FAQ
What Is the Zevra Therapeutics (ZVRA) Stock Price Today?
The Zevra Therapeutics stock price today is 8.65
What Stock Exchange Does Zevra Therapeutics Trade On?
Zevra Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Zevra Therapeutics?
The stock symbol for Zevra Therapeutics is "ZVRA."
What Is the Zevra Therapeutics Market Cap?
As of today, Zevra Therapeutics market cap is 472.98M.
What Is Zevra Therapeutics's Earnings Per Share (TTM)?
The Zevra Therapeutics EPS (TTM) is -1.86.
When Is the Next Zevra Therapeutics Earnings Date?
Zevra Therapeutics will release its next earnings report on 18 Aug 2025.
From a Technical Analysis Perspective, Is ZVRA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Zevra Therapeutics Stock Split?
Zevra Therapeutics has split 1 times.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.